Pharmaceutical intermediate Erythromycin Ethylsuccinate Powder

CAS:1264-62-6

MF: C43H75NO16

MW: 862.05

EINECS:215-033-8

Specification​: 99% min Erythromycin Ethylsuccinate Powder

Sample:Erythromycin Ethylsuccinate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Erythromycin Ethylsuccinate Usage and Synthesis.

Erythromycin Ethylsuccinate is a macrolide antibiotic which can be used in the treatment of the following infections in patients who are allergic or resistant to penicillin and other β-lactams: acute tonsillitis, acute pharyngitis, sinusitis due to haemolytic streptococcus, pneumococcus, etc.; scarlet fever, cellulitis due to haemolytic streptococcus; diphtheria and diphtheria carrier; gas gangrene, anthrax, tetanus: actinomycosis: syphilis; listeriosis, etc. , tetanus: actinomycosis: syphilis; listeriosis and so on.

Erythromycin Ethylsuccinate medical insurance type: Erythromycin Succinate Dispersible Tablets, Erythromycin Succinate Capsules, Erythromycin Succinate Granules, Erythromycin Succinate Tablets for medical insurance B class.

Uses and functions of Erythromycin Ethylsuccinate.

1, Erythromycin Ethylsuccinate can be used as penicillin and other β-lactam allergy or resistance to patients in the treatment of the following infections: hemolytic streptococcus, Streptococcus pneumoniae, etc. caused by acute tonsillitis, acute pharyngitis, sinusitis; hemolytic streptococcus caused by scarlet fever, cellulitis; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus: Actinomycosis: syphilis; listeriosis and so on.

2、Mycoplasma pneumoniae pneumonia.

3, Chlamydia pneumonia.

4, Chlamydia spp. and Mycoplasma spp. caused genitourinary tract infection.

Chlamydia trachomatis conjunctivitis.

6, anaerobic bacteria caused by oral infection.

7, Campylobacter jejuni enteritis.

8, Pertussis.

9, Legionnaires' disease.

10, rheumatic fever recurrence, infective endocarditis (rheumatic heart disease, congenital heart disease, cardiac membrane replacement) and oral cavity, upper respiratory tract medical operation of the prophylactic medicine (penicillin alternative medicine).

Producing an Effect of Erythromycin Ethylsuccinate.

1, Erythromycin Ethylsuccinate is a macrolide antibiotic, more stable than erythromycin in gastric acid, staphylococcus spp. (except methicillin-resistant strains), groups of streptococci and gram-positive bacilli have antibacterial activity.

Neisseria, Haemophilus influenzae, Bordetella pertussis are also sensitive to this product.

Erythromycin Ethylsuccinate is also antibacterial against various anaerobes except Clostridium fragilis and Clostridium perfringens. It also has inhibitory effect on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsiae and Chlamydiae and Chlamydiae.

2、Erythromycin Ethylsuccinate is a bacteriostatic agent, but also has bactericidal effect on some bacteria in high concentration. Staphylococcus genus (including enzyme-producing strains), various groups of streptococci and gram-positive bacilli have antibacterial activity.

Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to the product. The product also has antibacterial effect on all kinds of anaerobes except Clostridium perfringens and Clostridium difficile.

It can also inhibit Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia.

Erythromycin Ethylsuccinate crosses the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome in the proximity of the donor site (P-site), blocking the binding of transfer ribonucleic acid (t-RNA) to the P-site, and at the same time blocking the binding of polypeptide from the acceptor site ("A-site"). At the same time, it also blocked the displacement of the polypeptide chain from the acceptor site ("A" site) to the "P" site, thus inhibiting bacterial protein synthesis.

In vitro studies of  Bulk Erythromycin Ethylsuccinate Powder.

Erythromycin has antimicrobial activity against Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, M. catarrhalis, C. perfringens, Gonococcus, Campylobacter jejuni, Helicobacter pylori, and Burkholderia pseudomallei.

Erythromycin is a gastric actin receptor agonist, which is a potent agonist of gastrointestinal myokinetic activity.Erythromycin induces a 50% maximal contractile response to mega-doses of acetylcholine at a required concentration of 2 μM.

Replacing 50% labelled gastrokineticin, the concentration of Erythromycin required is 13 μM.Erythromycin has no effect on the muscularis propria of the duodenum in the rat or dog but induces contraction of the muscularis propria in humans.Erythromycin is a potent agonist of the gastrointestinal muscularis propria.